Cargando…

Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment

Conventional cancer chemotherapies often exhibit insufficient therapeutic outcomes and dose-limiting toxicity. Therefore, there is a need for novel therapeutics and formulations with higher efficacy, improved safety, and more favorable toxicological profiles. This has promoted the development of nan...

Descripción completa

Detalles Bibliográficos
Autores principales: Entzian, Kristin, Aigner, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397943/
https://www.ncbi.nlm.nih.gov/pubmed/34452096
http://dx.doi.org/10.3390/pharmaceutics13081135
_version_ 1783744720341565440
author Entzian, Kristin
Aigner, Achim
author_facet Entzian, Kristin
Aigner, Achim
author_sort Entzian, Kristin
collection PubMed
description Conventional cancer chemotherapies often exhibit insufficient therapeutic outcomes and dose-limiting toxicity. Therefore, there is a need for novel therapeutics and formulations with higher efficacy, improved safety, and more favorable toxicological profiles. This has promoted the development of nanomedicines, including systems for drug delivery, but also for imaging and diagnostics. Nanoparticles loaded with drugs can be designed to overcome several biological barriers to improving efficiency and reducing toxicity. In addition, stimuli-responsive nanocarriers are able to release their payload on demand at the tumor tissue site, preventing premature drug loss. This review focuses on ultrasound-triggered drug delivery by nanocarriers as a versatile, cost-efficient, non-invasive technique for improving tissue specificity and tissue penetration, and for achieving high drug concentrations at their intended site of action. It highlights aspects relevant for ultrasound-mediated drug delivery, including ultrasound parameters and resulting biological effects. Then, concepts in ultrasound-mediated drug delivery are introduced and a comprehensive overview of several types of nanoparticles used for this purpose is given. This includes an in-depth compilation of the literature on the various in vivo ultrasound-responsive drug delivery systems. Finally, toxicological and safety considerations regarding ultrasound-mediated drug delivery with nanocarriers are discussed.
format Online
Article
Text
id pubmed-8397943
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83979432021-08-29 Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment Entzian, Kristin Aigner, Achim Pharmaceutics Review Conventional cancer chemotherapies often exhibit insufficient therapeutic outcomes and dose-limiting toxicity. Therefore, there is a need for novel therapeutics and formulations with higher efficacy, improved safety, and more favorable toxicological profiles. This has promoted the development of nanomedicines, including systems for drug delivery, but also for imaging and diagnostics. Nanoparticles loaded with drugs can be designed to overcome several biological barriers to improving efficiency and reducing toxicity. In addition, stimuli-responsive nanocarriers are able to release their payload on demand at the tumor tissue site, preventing premature drug loss. This review focuses on ultrasound-triggered drug delivery by nanocarriers as a versatile, cost-efficient, non-invasive technique for improving tissue specificity and tissue penetration, and for achieving high drug concentrations at their intended site of action. It highlights aspects relevant for ultrasound-mediated drug delivery, including ultrasound parameters and resulting biological effects. Then, concepts in ultrasound-mediated drug delivery are introduced and a comprehensive overview of several types of nanoparticles used for this purpose is given. This includes an in-depth compilation of the literature on the various in vivo ultrasound-responsive drug delivery systems. Finally, toxicological and safety considerations regarding ultrasound-mediated drug delivery with nanocarriers are discussed. MDPI 2021-07-26 /pmc/articles/PMC8397943/ /pubmed/34452096 http://dx.doi.org/10.3390/pharmaceutics13081135 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Entzian, Kristin
Aigner, Achim
Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title_full Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title_fullStr Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title_full_unstemmed Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title_short Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment
title_sort drug delivery by ultrasound-responsive nanocarriers for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397943/
https://www.ncbi.nlm.nih.gov/pubmed/34452096
http://dx.doi.org/10.3390/pharmaceutics13081135
work_keys_str_mv AT entziankristin drugdeliverybyultrasoundresponsivenanocarriersforcancertreatment
AT aignerachim drugdeliverybyultrasoundresponsivenanocarriersforcancertreatment